UPC on Nasdaq
Universe Pharmaceuticals INC
Universe Pharmaceuticals INC is a Chinese pharmaceutical preparations company, incorporated in China.1 It is headquartered in Jiangxi, China.1 Its shares trade on Nasdaq under the symbol UPC.1
$3.96 down 0.18 (4.46%)Price as of Oct 16, 2026 at 19:58 UTC
Last updated Oct 21, 2026.
Overview
Compare with Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals or Viatris, or pick any stock.
- TickerUPC on Nasdaq1
- IndustryPharmaceutical Preparations1
- HeadquartersJiangxi, China1
- Incorporated inChina4
- Business address265 Jingjiu Avenue, Jinggangshan Econ. And Tech. Dev. Zone, Ji'An, Jiangxi, F4 3431004
- Filer categoryNon-accelerated filer, Emerging growth company4
See how the biggest companies compare on our leaderboards
For risks facing our Company as a result of our organizational structure and doing business in China, see “Item 3. Key Information—D.5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Revenue From Sales Of Selfmanufactured TCMDProducts brought in 74% of the revenue Universe Pharmaceuticals INC broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue From Sales Of Selfmanufactured TCMDProducts | $18.6B | $14.0B | $13.3B |
| Revenue From Sales Of Thirdparty Products | $13.7B | $9.0B | $4.6B |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue65¢$11.6B
- Research and development4¢$671.8M
- Other costs30¢$5.3B
- Interest2¢$289.4M
Out of $17.9B in revenue.3 The company lost money this year.
Financial statements
No quarterly figures reported.
Every line of the income statement as filed: the last 3 fiscal years, latest first.3
| Period ending | 2025-09-30 | 2024-09-30 | 2023-09-30 |
|---|---|---|---|
| Revenue | $17.9B | $23.0B | $32.3B |
| Cost of revenue | -$11.6B | -$17.0B | -$22.0B |
| Gross profit | $6.3B | $6.1B | $10.3B |
| Selling expenses | -$4.8B | -$8.2B | -$6.8B |
| General and administrative expenses | -$3.7B | -$2.9B | -$2.6B |
| Research and development expenses | -$671.8M | -$3.0B | -$4.9B |
| Total operating expenses | -$9.2B | -$14.1B | -$14.3B |
| Loss from operations | -$2.9B | -$8.0B | -$4.0B |
| Interest expense, net | -$232.0M | -$278.2M | -$156.8M |
| Other (expense) income, net | -$108.0M | $145.5M | -$235.6M |
| Impairment of prepayments for construction in progress | -$481.1M | ||
| Equity investment income | $65.1M | $31.9M | $31.1M |
| Total other expense, net | -$756.1M | -$100.8M | -$361.3M |
| Loss before income tax expense | -$3.7B | -$8.1B | -$4.3B |
| Income tax expense | -$606.7M | -$2.3B | |
| Net loss | -$3.7B | -$8.7B | -$6.6B |
| Foreign currency translation adjustment | -$701.4M | $1.3B | -$779.4M |
| Total Comprehensive loss | -$4.4B | -$7.5B | -$7.4B |
| Net loss per share - Basic (in Dollars per share) | -$8.06 | -$626.96 | -$1,089.21 |
| Net loss per share - Diluted (in Dollars per share) | -$8.06 | -$626.96 | -$1,089.21 |
| Weighted average number of shares outstanding used in calculating basic and diluted loss per share (in Shares) | 455.9K shares | 13.9K shares | 6.0K shares |
| Weighted average number of shares outstanding used in calculating diluted loss per share (in Shares) | 455.9K shares | 13.9K shares | 6.0K shares |
No quarter-by-quarter statement was filed.
No quarterly figures reported.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.3
| Period ending | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Cash | $33.6B | $29.5B | ||
| Accounts receivable, net | $13.0B | $12.9B | ||
| Inventories, net | $2.2B | $1.7B | ||
| Advance to suppliers | $2.5B | $978.2M | ||
| Other receivable | $2.3B | $5.7B | ||
| Prepaid expenses and other current assets | $39.9M | $852.4M | ||
| TOTAL CURRENT ASSETS | $53.6B | $51.6B | ||
| Property, plant and equipment, net | $3.6B | $3.6B | ||
| Prepayments for construction in progress | $8.9B | $9.5B | ||
| Intangible assets, net | $296.8M | $262.9M | ||
| Investment in equity securities | 702.3M CNY | 5.0M CNY | 5.0M CNY | |
| TOTAL NON-CURRENT ASSETS | $15.7B | $16.3B | ||
| TOTAL ASSETS | $69.3B | $68.0B | ||
| Short-term bank loans | $7.1B | $5.9B | ||
| Current portion of long-term bank loans | $2.1B | |||
| Accounts payable | $1.7B | $4.9B | ||
| Contract liabilities | $40.7M | |||
| Taxes payable | $640.8M | $1.0B | ||
| Other payable | $856.6M | $1.3B | ||
| Accrued expenses and other current liabilities | $262.6M | $352.9M | ||
| TOTAL CURRENT LIABILITIES | $13.2B | $20.3B | ||
| Long-term bank loans | $2.1B | |||
| TOTAL NON-CURRENT LIABILITY | $2.1B | |||
| TOTAL LIABILITIES | $13.2B | $22.5B | ||
| Ordinary shares, $11.25 par value, 2,000,000,000 shares authorized, 563,338 and 42,880 shares issued and outstanding as of September 30, 2025 and 2024, respectively | $6.3B | $482.4M | ||
| Additional paid in capital | $63.0B | $53.9B | ||
| Statutory reserve | $2.4B | $2.4B | ||
| Accumulated deficit | -$13.8B | -$10.2B | ||
| Accumulated other comprehensive loss | -$1.8B | -$1.1B | ||
| TOTAL SHAREHOLDERS EQUITY | $56.1B | $45.5B | $28.0B | $35.3B |
| TOTAL LIABILITIES AND SHAREHOLDERS EQUITY | $69.3B | $68.0B | ||
| Ordinary shares, par value (in Dollars per share) | $11.25 | $11.25 | ||
| Ordinary shares, shares authorized (in Shares) | 2.0B shares | 2.0B shares | ||
| Ordinary shares, shares issued (in Shares) | 563.3K shares | 42.9K shares | ||
| Ordinary shares, shares outstanding (in Shares) | 563.3K shares | 42.9K shares |
| Period ending | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Cash | $33.6B | $29.5B | ||
| Accounts receivable, net | $13.0B | $12.9B | ||
| Inventories, net | $2.2B | $1.7B | ||
| Advance to suppliers | $2.5B | $978.2M | ||
| Other receivable | $2.3B | $5.7B | ||
| Prepaid expenses and other current assets | $39.9M | $852.4M | ||
| TOTAL CURRENT ASSETS | $53.6B | $51.6B | ||
| Property, plant and equipment, net | $3.6B | $3.6B | ||
| Prepayments for construction in progress | $8.9B | $9.5B | ||
| Intangible assets, net | $296.8M | $262.9M | ||
| Investment in equity securities | 702.3M CNY | 5.0M CNY | 5.0M CNY | |
| TOTAL NON-CURRENT ASSETS | $15.7B | $16.3B | ||
| TOTAL ASSETS | $69.3B | $68.0B | ||
| Short-term bank loans | $7.1B | $5.9B | ||
| Current portion of long-term bank loans | $2.1B | |||
| Accounts payable | $1.7B | $4.9B | ||
| Contract liabilities | $40.7M | |||
| Taxes payable | $640.8M | $1.0B | ||
| Other payable | $856.6M | $1.3B | ||
| Accrued expenses and other current liabilities | $262.6M | $352.9M | ||
| TOTAL CURRENT LIABILITIES | $13.2B | $20.3B | ||
| Long-term bank loans | $2.1B | |||
| TOTAL NON-CURRENT LIABILITY | $2.1B | |||
| TOTAL LIABILITIES | $13.2B | $22.5B | ||
| Ordinary shares, $11.25 par value, 2,000,000,000 shares authorized, 563,338 and 42,880 shares issued and outstanding as of September 30, 2025 and 2024, respectively | $6.3B | $482.4M | ||
| Additional paid in capital | $63.0B | $53.9B | ||
| Statutory reserve | $2.4B | $2.4B | ||
| Accumulated deficit | -$13.8B | -$10.2B | ||
| Accumulated other comprehensive loss | -$1.8B | -$1.1B | ||
| TOTAL SHAREHOLDERS EQUITY | $56.1B | $45.5B | $28.0B | $35.3B |
| TOTAL LIABILITIES AND SHAREHOLDERS EQUITY | $69.3B | $68.0B | ||
| Ordinary shares, par value (in Dollars per share) | $11.25 | $11.25 | ||
| Ordinary shares, shares authorized (in Shares) | 2.0B shares | 2.0B shares | ||
| Ordinary shares, shares issued (in Shares) | 563.3K shares | 42.9K shares | ||
| Ordinary shares, shares outstanding (in Shares) | 563.3K shares | 42.9K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.3
| Period ending | 2025-09-30 | 2024-09-30 | 2023-09-30 |
|---|---|---|---|
| Net loss | -$3.7B | -$8.7B | -$6.6B |
| Depreciation and amortization | $517.4M | $485.7M | $508.8M |
| Loss from disposal of property, plant and equipment | $2.9M | $4.0M | $114.0K |
| (Reversal) allowance for credit loss | -$113.5M | $131.6M | |
| Allowance (reversal) of inventory reserve | $50.7M | -$49.2M | |
| Deferred income tax expense | $606.7M | $1.6B | |
| Impairment of prepayments for construction in progress | $481.1M | ||
| Accounts receivable | -$169.0M | -$1.5B | $4.7B |
| Inventory, net | -$474.6M | $1.6B | -$1.2B |
| Advance to suppliers, net | -$1.5B | -$769.9M | -$170.0M |
| Other receivable | $3.3B | -$158.0M | $391.6M |
| Prepaid expenses and other current assets | $790.0M | -$792.7M | $696.1M |
| Deferred tax assets | -$948.0M | ||
| Prepaid expenses-related party, non-current | $36.3M | ||
| Accounts payable | -$3.1B | $143.7M | $1.6B |
| Contract liabilities | $40.2M | ||
| Taxes payable | -$324.5M | $554.4M | $280.9M |
| Other payable | -$706.1M | -$1.1B | $74.0M |
| Accrued expenses and other current liabilities | -$85.4M | -$31.5M | $170.0M |
| Net cash (used in) provided by operating activities | -$5.1B | -$9.5B | $1.1B |
| Purchases of property, plant and equipment | -$266.8M | -$208.3M | -$44.2M |
| Prepayments for construction in progress | -$37.5M | ||
| Purchase of intangible asset | -$80.4M | -$117.3M | |
| Proceeds from disposal of property, plant and equipment | $5.4M | $1.8M | |
| Net cash used in investing activities | -$341.8M | -$361.3M | -$44.2M |
| Net proceeds from issuance of ordinary shares | $15.0B | $25.0B | |
| Proceeds from bank loans | $7.1B | $7.8B | $5.7B |
| Repayment of bank loans | -$5.7B | -$5.6B | -$4.0B |
| Proceeds from related parties borrowings | $3.2B | $9.5B | $3.5B |
| Repayments of related parties borrowings | -$9.8B | -$2.8B | -$6.6B |
| Net cash provided by (used in) financing activities | $9.7B | $34.0B | -$1.4B |
| Effect of exchange rate changes on cash | -$237.7M | $126.1M | -$108.2M |
| Net increase (decrease) in cash | $4.1B | $24.2B | -$426.2M |
| Cash paid for interest | $289.4M | $304.5M | $190.2M |
| Cash paid for income tax | $863.8M | ||
| Obtaining property, plant and equipment | $282.2M | $342.5M |
No quarter-by-quarter statement was filed.
Corporate structure
Universe Pharmaceuticals INC sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Universe Pharmaceuticals INC
- Chengming Tang Filed SCHEDULE 13G on Universe Pharmaceuticals INC, latest Sep 1, 2026
- Chunhua Zheng Filed SCHEDULE 13G on Universe Pharmaceuticals INC, latest Sep 1, 2026
- Lu (nmn) Yang Filed SCHEDULE 13G on Universe Pharmaceuticals INC, latest Sep 1, 2026
- Piao Ye Filed SCHEDULE 13G on Universe Pharmaceuticals INC, latest Sep 1, 2026
- Shan Xie Filed SCHEDULE 13G on Universe Pharmaceuticals INC, latest Sep 1, 2026
- Shanshan Lu Filed SCHEDULE 13G on Universe Pharmaceuticals INC, latest Sep 1, 2026
- Xuefeng Li Filed SCHEDULE 13G on Universe Pharmaceuticals INC, latest Sep 1, 2026
- Xuncheng Chen Filed SCHEDULE 13G on Universe Pharmaceuticals INC, latest Sep 1, 2026
- Gang Lai Filed SCHEDULE 13D on Universe Pharmaceuticals INC, latest May 21, 2026
- SABBY MANAGEMENT, LLC Filed SCHEDULE 13G/A on Universe Pharmaceuticals INC, latest Jan 7, 2026 (2 filings since Jan 3, 2025)
- Anson Funds Management LP Filed SCHEDULE 13G/A on Universe Pharmaceuticals INC, latest May 15, 2025 (2 filings since Feb 14, 2025)
- PURA VIDA INVESTMENTS, LLC Filed SC 13G/A on Universe Pharmaceuticals INC, latest Feb 14, 2023 (2 filings since Dec 28, 2021)
- Universe Pharmaceuticals INC Jiangxi, China
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Universe Pharmaceuticals INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $10.5B3 Sep 30, 2025 | $10.2B3 Sep 30, 2024 | +2.5% |
| Accumulated depreciation | $6.9B3 Sep 30, 2025 | $6.7B3 Sep 30, 2024 | +3.6% |
| Property and equipment, net | $3.6B3 Sep 30, 2025 | $3.6B3 Sep 30, 2024 | +0.4% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Stakes in other companies (equity method) | $702.3M3 Sep 30, 2025 | $712.5M3 Sep 30, 2024 | −1.4% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Intangible assets, net (excluding goodwill) | $296.8M3 Sep 30, 2025 | $262.9M3 Sep 30, 2024 | +12.9% |
| Finite-lived intangibles, gross | $473.9M3 Sep 30, 2025 | $398.1M3 Sep 30, 2024 | +19.0% |
| Accumulated amortization | $177.1M3 Sep 30, 2025 | $135.3M3 Sep 30, 2024 | +31.0% |
Inventory
Leadership
Who has led Universe Pharmaceuticals INC, and when. Pick a name to see everywhere that person has worked.
- Chief executive officerGang Lai Mar 18, 2026 to now10
- Chief operating officerBaochang Liu Mar 18, 2026 to now11
Board members and other officers (4)
- Board memberDing Zheng Mar 18, 2026 to now12
- Board memberGang Lai Mar 18, 2026 to now10
- Board memberJiawen Pang Mar 18, 2026 to now13
- Board memberYongping Yu Mar 18, 2026 to now14
Timeline
- Mar 18, 2026New chief executive Gang Lai becomes CEO10
Filings
89 filings to the SEC since October 2021: 5 annual reports, 7 insider forms, 16 large holders, 61 other. The latest 20:
- Oct 9, 2026EFFECT EDGAR
- Oct 6, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Sep 29, 2026F-3 REGISTRATION STATEMENT EDGAR
- Sep 3, 20266-K/A AMENDMENT NO. 1 TO FORM 6-K EDGAR
- Sep 1, 2026SCHEDULE 13G EDGAR
- Sep 1, 2026SCHEDULE 13G EDGAR
- Sep 1, 2026SCHEDULE 13G EDGAR
- Sep 1, 2026SCHEDULE 13G EDGAR
- Sep 1, 2026SCHEDULE 13G EDGAR
- Sep 1, 2026SCHEDULE 13G EDGAR
- Sep 1, 2026SCHEDULE 13G EDGAR
- Sep 1, 2026SCHEDULE 13G EDGAR
- Sep 1, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jul 31, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jul 29, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jun 26, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- May 21, 20264 EDGAR
- May 21, 2026SCHEDULE 13D EDGAR
- May 14, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Apr 16, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
The 89 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Chengming TangSCHEDULE 13G, 1 filing Sep 1, 202615
- Chunhua ZhengSCHEDULE 13G, 1 filing Sep 1, 202616
- Lu (nmn) YangSCHEDULE 13G, 1 filing Sep 1, 202617
- Piao YeSCHEDULE 13G, 1 filing Sep 1, 202618
- Shan XieSCHEDULE 13G, 1 filing Sep 1, 202619
- Shanshan LuSCHEDULE 13G, 1 filing Sep 1, 202620
- Xuefeng LiSCHEDULE 13G, 1 filing Sep 1, 202621
- Xuncheng ChenSCHEDULE 13G, 1 filing Sep 1, 202622
- Gang LaiSCHEDULE 13D, 1 filing May 21, 202623
- SABBY MANAGEMENT, LLCSCHEDULE 13G/A, 2 filings Jan 3, 2025 to Jan 7, 202624
- Anson Funds Management LPSCHEDULE 13G/A, 2 filings Feb 14, 2025 to May 15, 202525
- PURA VIDA INVESTMENTS, LLCSC 13G/A, 2 filings Dec 28, 2021 to Feb 14, 202326
- Sununion Holding Group LtdSC 13G, 1 filing Feb 11, 202227
SEC filer profile
How Universe Pharmaceuticals INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARUniverse Pharmaceuticals INC1
- CIK0001809616
- Filer statusNon-accelerated filer an emerging growth company; not a shell company5
- Incorporated inCayman Islands5
- Fiscal year endsSeptember 301
- Industry code (SIC)2834 Pharmaceutical Preparations1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address265 Jingjiu Avenue, Jinggangshan Econ. And Tech. Dev. Zone, Ji'An, Jiangxi, F4 3431001
- Phone86-0796-84033091
- Shares outstanding563,338 shares as of Sep 30, 20255
- AuditorEnrome LLP, Singapore PCAOB ID 6907; no auditor attestation of internal control over financial reporting5
- On EDGAR sinceApr 24, 20201
- Filings119 in all: 6-K (49), SCHEDULE 13G (10), CORRESP (8), 3 (6), UPLOAD (6), 20-F (5), F-1/A (5), EFFECT (4)1
All 25 form types
FWP (4), 424B4 (2), F-1 (2), F-3 (2), NT 20-F (2), SC 13G (2), SCHEDULE 13G/A (2), 4 (1), 424B5 (1), 6-K/A (1), 8-A12B (1), CERT (1), DRS (1), DRS/A (1), DRSLTR (1), SC 13G/A (1), SCHEDULE 13D (1)
- Latest filingsAnnual report (20-F) Jan 29, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Ordinary Shares | UPC | Nasdaq |
From the cover page of the 20-F filed Jan 29, 2026 (Section 12(b) of the Exchange Act).5
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2Yahoo FinanceUPC quote
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10SEC EDGARGang Lai, Chief executive officer
- 11
- 12SEC EDGARDing Zheng, Board member
- 13SEC EDGARJiawen Pang, Board member
- 14SEC EDGARYongping Yu, Board member
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27